跳至主要内容
临床试验/NCT01369680
NCT01369680已完成1 期

Oral Ketamine for Control of Chronic Pain in Children

University of Rochester1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
1
主要终点
Number of Participants Tolerating Dose

研究概览

简要总结

The study is a maximum tolerated dose finding study for oral, chronic, daily administration of oral ketamine (by mouth) in children with long-term daily pain.

详细描述

Pain control in children is a major concern when children have chronic diseases, such as cancer and sickle cell disease with frequent pain crises. Additionally, though the traditional pain medications of morphine and acetaminophen are regarded as safe and effective for pain control in children, there are few alternative therapies available when these medications are insufficient. Chronic pain (whether cancer or non-cancer pain) in children has few approved and well tolerated therapeutic options with proven efficacy.

Ketamine is a medication that was first described in 1962[1]. It is an NMDA-R (N-methyl-D-aspartate-receptor) antagonist with dissociative amnestic and analgesic effects[1-2]. Ketamine is particularly successful as a dissociative amnestic for children in the emergent setting as it has little respiratory or cardiac impact, has a short half-life, and has fewer psychomimetic effects in the pediatric population than in adults[1]. Its function is via antagonism and reduction of NMDA-receptors in the afferent pain pathway. In effect, this decreases pain receptors and can dramatically reduce the need for narcotic pain medications for patients with chronic pain.

Unfortunately, with such dissociative effects, ketamine has been a drug of abuse for decades[1,3]. Additionally, there is concern that ketamine may have long-term deleterious effects on cognition for those subjects chronically exposed to IV ketamine[4], especially children whose neural pathways may still be developing[1,5]. These effects may include difficulty with attention and working memory, though the effects appear to be short-term and reversible in adults. However, much of this data is derived from rodent or primate studies, and there is little evidence that there are long-term cognitive effects on humans chronically exposed to ketamine[1]. This lack of data is particularly impactful in the pediatric group.

Ketamine has been evaluated as an analgesic medication for patients with chronic pain that is not resolved with narcotics and gabapentin. There are a number of case reports and small case series that suggest ketamine is a useful medication for control of chronic pain in adults[2,4,6-8]. Additionally, there are case studies that describe lasting (12 week) pain control in adults after 4-10 days of ketamine therapy[7-8]. However, there are, to date, little data that aid a pediatrician in determining if ketamine is a safe and effective option as a chronic, oral therapy for children with chronic pain.

Overall, there are few proven safe and effective medications for use in chronic pain management for children. Ketamine is a well known medication with a well elaborated safety profile, when given intravenously and for short periods of time. There is, as above, emerging data that ketamine is useful for chronic pain control in adults. The question that remains to be answered is whether ketamine is a safe option for chronic use in children, whose brains are significantly more plastic and whose metabolism is different compared with those of adults.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
8 Years 至 22 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Subject, parent, or guardian willing and able to give informed consent
  • NRS for pain >4
  • Chronic pain, which has been present for >3 months, or persisting longer than is normal for the underlying diagnosis
  • Chronic pain related to diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)
  • Able to tolerate and cooperate with neurocognitive assessment
  • Age 8-22 years old

排除标准

  • If they are known or suspected to have drug dependence or addiction
  • History of psychiatric disorder such as depression, schizophrenia, or bipolar disorder
  • History of hypertension
  • Unable to cooperate with neurocognitive assessment
  • Chronic pain related to chronic abdominal pain syndrome
  • Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.
  • Previous intolerance or allergic reaction to ketamine
  • Pregnancy
  • Use of CYP3A4 inhibitors or inducers within the 2 week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
  • Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.

研究组 & 干预措施

Ketamine 0.25 mg/kg/dose

Experimental

The first three subjects were administered 0.25 mg/kg/dose oral ketamine.

干预措施: Ketamine (Drug)

Ketamine 0.5 mg/kg/dose

Experimental

The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.

干预措施: Ketamine (Drug)

Ketamine 1 mg/kg/dose

Experimental

The third group of three subjects were administered 1 mg/kg/dose oral ketamine.

干预措施: Ketamine (Drug)

Ketamine 1.5 mg/kg/dose

Experimental

The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.

干预措施: Ketamine (Drug)

结局指标

主要结局

Number of Participants Tolerating Dose

时间窗: Up to 2 weeks

According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity.

次要结局

  • Neurocognitive Effect(At 14 weeks)
  • Norketamine Cmax (Measured in ng/mL).(At week 1)
  • Pain Control(Week 2)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David Korones

Director, Pediatric Palliative Care

University of Rochester

研究点 (1)

Loading locations...

相似试验